EA201891628A1 - Ингибирование аллергической реакции с использованием ингибитора il-33 - Google Patents

Ингибирование аллергической реакции с использованием ингибитора il-33

Info

Publication number
EA201891628A1
EA201891628A1 EA201891628A EA201891628A EA201891628A1 EA 201891628 A1 EA201891628 A1 EA 201891628A1 EA 201891628 A EA201891628 A EA 201891628A EA 201891628 A EA201891628 A EA 201891628A EA 201891628 A1 EA201891628 A1 EA 201891628A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
inhibition
allergic reactions
mammal
inhibiting
Prior art date
Application number
EA201891628A
Other languages
English (en)
Inventor
Марко Лонди
Original Assignee
Анаптисбайо, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анаптисбайо, Инк. filed Critical Анаптисбайо, Инк.
Publication of EA201891628A1 publication Critical patent/EA201891628A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Способ ингибирования или предотвращения аллергической реакции, конкретно на пищевой антиген, у млекопитающего, который включает введение млекопитающему ингибитора IL-33.
EA201891628A 2016-01-14 2017-01-17 Ингибирование аллергической реакции с использованием ингибитора il-33 EA201891628A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278671P 2016-01-14 2016-01-14
PCT/US2017/013818 WO2017124110A1 (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Publications (1)

Publication Number Publication Date
EA201891628A1 true EA201891628A1 (ru) 2018-12-28

Family

ID=59311527

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891628A EA201891628A1 (ru) 2016-01-14 2017-01-17 Ингибирование аллергической реакции с использованием ингибитора il-33

Country Status (12)

Country Link
US (1) US20190016795A1 (ru)
EP (1) EP3402521A4 (ru)
JP (1) JP2019508382A (ru)
KR (1) KR20180101533A (ru)
CN (1) CN109475622A (ru)
AU (1) AU2017208099A1 (ru)
BR (1) BR112018014247A2 (ru)
CA (1) CA3011547A1 (ru)
EA (1) EA201891628A1 (ru)
MX (1) MX2018008732A (ru)
SG (2) SG10202006699XA (ru)
WO (1) WO2017124110A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016016020B1 (pt) 2014-01-10 2024-02-27 Anaptysbio, Inc Agente de ligação (il-33) de interleucina-33, célula procariótica isolada, composição e uso do referido agente
EP3448888A1 (en) 2016-04-27 2019-03-06 Pfizer Inc Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
GB201712952D0 (en) * 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
US20200239562A1 (en) * 2017-10-09 2020-07-30 Anaptysbio, Inc. Anti-il-33 therapy for atopic dermatitis
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560530B1 (en) * 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
US8119771B2 (en) * 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (ar) * 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9637535B2 (en) * 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
KR101567758B1 (ko) * 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
CN105980556B (zh) * 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
BR112016016020B1 (pt) * 2014-01-10 2024-02-27 Anaptysbio, Inc Agente de ligação (il-33) de interleucina-33, célula procariótica isolada, composição e uso do referido agente

Also Published As

Publication number Publication date
EP3402521A4 (en) 2019-11-20
US20190016795A1 (en) 2019-01-17
JP2019508382A (ja) 2019-03-28
CA3011547A1 (en) 2017-07-20
CN109475622A (zh) 2019-03-15
KR20180101533A (ko) 2018-09-12
SG11201805900YA (en) 2018-08-30
EP3402521A1 (en) 2018-11-21
AU2017208099A1 (en) 2018-08-09
WO2017124110A1 (en) 2017-07-20
MX2018008732A (es) 2018-12-06
SG10202006699XA (en) 2020-08-28
BR112018014247A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
EA201891628A1 (ru) Ингибирование аллергической реакции с использованием ингибитора il-33
CY1123557T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201691421A1 (ru) Гетероарилы и их применение
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
DK3341379T3 (da) EZH2-hæmmere
WO2015197874A3 (en) Combination of cd95/cd95l inhibition and cancer immunotherapy
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
AU2017247004A1 (en) Method of treating atherosclerosis
SV2018005613A (es) Agentes, usos y metodos para el tratamiento
MA55477A (fr) Inhibiteurs de hpk1
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
CL2017000074A1 (es) Antagonistas de reproducción de peces